Kindred Stock Analysis

KIN -  USA Stock  

USD 9.15  0.02  0.22%

The latest price rise of Kindred Biosciences may raise some interest from institutional investors. The stock closed today at a share price of 9.15 on 1,459 in trading volume. The company executives may have good odds in positioning the firm resources to exploit market volatility in August. The stock standard deviation of daily returns for 90 days investing horizon is currently 7.18. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Kindred Biosciences partners.
Please see Stocks Correlation.

Search Stock Analysis 

 
Refresh
The Kindred Biosciences stock analysis report makes it easy to digest most publicly released information about Kindred Biosciences and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Kindred Stock analysis module also helps to analyze the Kindred Biosciences price relationship with some important fundamental indicators such as market cap and management efficiency.

Kindred Stock Analysis Notes

About 70.0% of the company shares are owned by institutional investors. The book value of Kindred Biosciences was now reported as 1.87. The company recorded a loss per share of 0.22. Kindred Biosciences had not issued any dividends in recent years. Kindred Biosciences, Inc., a commercial-stage biopharmaceutical company, engages in developing therapies for pets. The company was incorporated in 2012 and is headquartered in Burlingame, California. Kindred Biosciences operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 63 people. To find out more about Kindred Biosciences contact Richard Chin at 650 701-7901 or learn more at www.kindredbio.com.

Kindred Biosciences Quarterly Cost of Revenue

590,000Share

Kindred Biosciences Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Kindred Biosciences' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Kindred Biosciences or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Kindred Biosciences is way too risky over 90 days horizon
Kindred Biosciences appears to be risky and price may revert if volatility continues
The company reported the last year's revenue of 5.26 M. Reported Net Loss for the year was (8.78 M) with loss before taxes, overhead, and interest of (1.16 M).
Kindred Biosciences has about 63.15 M in cash with (2.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.39.
Roughly 70.0% of the company shares are owned by institutional investors
Latest headline from finance.yahoo.com: INVESTIGATION Halper Sadeh LLP Investigates LONE, KIN, GRA, ADXS Shareholders are Encouraged to Contact the Firm - Yahoo Finance

Kindred Biosciences Upcoming and Recent Events

Earnings reports are used by Kindred Biosciences to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Kindred Biosciences previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report4th of August 2021
Next Earnings Report8th of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End15th of March 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Kindred Largest EPS Surprises

Earnings surprises can significantly impact Kindred Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2017-11-07
2017-09-30-0.3267-0.290.036711 
2017-05-03
2017-03-31-0.34-0.30.0411 
2018-03-01
2017-12-31-0.308-0.35-0.04213 
View All Earnings Estimates

Kindred Biosciences SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Kindred Biosciences prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Kindred Biosciences investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Kindred Biosciences specific information freely available to individual and institutional investors to make a timely investment decision.
12th of July 2021
Unclassified Corporate Event
View
1st of July 2021
Financial Statements and Exhibits. Entry into a Material Definitive Agreement
View
30th of June 2021
Unclassified Corporate Event
View
25th of June 2021
Unclassified Corporate Event
View
24th of June 2021
Unclassified Corporate Event
View
23rd of June 2021
Submission of Matters to a Vote of Security Holders
View
16th of June 2021
Financial Statements and Exhibits. Other Events. Entry into a Material Definitive Agreement
View
2nd of June 2021
Financial Statements and Exhibits. Other Events
View

Kindred Market Capitalization

The company currently falls under 'Small-Cap' category with total capitalization of 414.77 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Kindred Biosciences's market, we take the total number of its shares issued and multiply it by Kindred Biosciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Kindred Profitablity

Kindred Biosciences' profitability indicators refer to fundamental financial ratios that showcase Kindred Biosciences' ability to generate income relative to its revenue or operating costs. If, let's say, Kindred Biosciences is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Kindred Biosciences' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Kindred Biosciences' profitability requires more research than a typical breakdown of Kindred Biosciences' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Net Profit Margin of (166.95) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (815.72) %, which entails that for every $100 of revenue, it lost -8.16.
Last ReportedProjected for 2021
Return on Investment(21.21) (22.88) 
Return on Average Assets(0.21) (0.23) 
Return on Average Equity(0.30) (0.32) 
Return on Invested Capital(0.22) (0.22) 
Return on Sales(0.52) (0.56) 

Management Efficiency

The entity has Return on Asset of (26.44) % which means that on every $100 spent on asset, it lost $26.44. This is way below average. In the same way, it shows return on shareholders equity (ROE) of (12.15) %, meaning that it generated no profit with money invested by stockholders. Kindred Biosciences management efficiency ratios could be used to measure how well kindred biosciences manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return on Investment is estimated to slide to -22.88. The value of Return on Average Assets is estimated to slide to -0.23. Kindred Biosciences Net Current Assets as percentage of Total Assets are quite stable at the moment as compared to the past year. The company's current value of Net Current Assets as percentage of Total Assets is estimated at 77.29. Asset Turnover is expected to rise to 0.44 this year, although the value of Return on Average Assets will most likely fall to (0.23) .
Last ReportedProjected for 2021
Book Value per Share 1.72  1.76 
Enterprise Value over EBIT(8.00) (8.63) 
Enterprise Value over EBITDA(10.33) (11.15) 
Price to Book Value 2.52  2.77 
Tangible Assets Book Value per Share 2.44  3.29 
Enterprise Value176.9 M196.1 M
Tangible Asset Value95.8 M96.5 M

Technical Drivers

As of the 23rd of July, Kindred Biosciences secures the Downside Deviation of 2.64, risk adjusted performance of 0.1385, and Mean Deviation of 3.47. Kindred Biosciences technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to collect and analyze data for nineteen technical drivers for Kindred Biosciences, which can be compared to its peers in the industry. Please verify Kindred Biosciences standard deviation, maximum drawdown, as well as the relationship between the Maximum Drawdown and expected short fall to decide if Kindred Biosciences is priced some-what accurately, providing market reflects its recent price of 9.15 per share. Given that Kindred Biosciences has jensen alpha of 1.23, we recommend you to check Kindred Biosciences's last-minute market performance to make sure the company can sustain itself at a future point.

Kindred Biosciences Price Movement Analysis

The output start index for this execution was nine with a total number of output elements of fifty-two. The Exponential Moving Average is calculated by weighting recent values of Kindred Biosciences more heavily than older values. View also all equity analysis or get more info about exponential moving average overlap studies indicator.

Kindred Biosciences Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Kindred Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Kindred Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Kindred Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Richard Chin over two weeks ago via Macroaxis 
Sale by Richard Chin of 40000 shares of Kindred Biosciences
Elanco Animal Health Inc over three weeks ago via Macroaxis 
Kindred Biosciences exotic insider transaction detected
Richard Chin over a month ago via Macroaxis 
Sale by Richard Chin of 40000 shares of Kindred Biosciences
Park West Asset Management Llc over a month ago via Macroaxis 
Sale by Park West Asset Management Llc of 345383 shares of Kindred Biosciences
Denise Bevers over three months ago via Macroaxis 
Exercise or conversion by Denise Bevers of 8396 shares of Kindred Biosciences subject to Rule 16b-3
Park West Asset Management Llc over three months ago via Macroaxis 
Acquisition or disposition of Kindred Biosciences securities by Park West Asset Management Llc
Denise Bevers over three months ago via Macroaxis 
Exercise or conversion by Denise Bevers of 4622 shares of Kindred Biosciences subject to Rule 16b-3
Lien Lyndon over three months ago via Macroaxis 
Acquisition by Lien Lyndon of 47000 shares of Kindred Biosciences subject to Rule 16b-3
Richard Chin over three months ago via Macroaxis 
Exercise or conversion by Richard Chin of 12500 shares of Kindred Biosciences subject to Rule 16b-3
Park West Asset Management Llc over three months ago via Macroaxis 
Sale by Park West Asset Management Llc of 3300 shares of Kindred Biosciences
Hangjun Zhan over three months ago via Macroaxis 
Exercise or conversion by Hangjun Zhan of 6250 shares of Kindred Biosciences subject to Rule 16b-3
Mccracken Joseph S over six months ago via Macroaxis 
Acquisition by Mccracken Joseph S of 48500 shares of Kindred Biosciences subject to Rule 16b-3

Kindred Biosciences Predictive Daily Indicators

Kindred Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Kindred Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Kindred Biosciences Forecast Models

Kindred Biosciences time-series forecasting models is one of many Kindred Biosciences' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Kindred Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Kindred Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Kindred Biosciences stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Kindred shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Kindred Biosciences. By using and applying Kindred Stock analysis, traders can create a robust methodology for identifying Kindred entry and exit points for their positions.
Last ReportedProjected for 2021
Operating Margin(42.62) (45.98) 
EBITDA Margin(0.41) (0.44) 
Gross Margin 0.89  0.97 
Profit Margin(0.52) (0.56) 
Kindred Biosciences, Inc., a commercial-stage biopharmaceutical company, engages in developing therapies for pets. The company was incorporated in 2012 and is headquartered in Burlingame, California. Kindred Biosciences operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 63 people.

Current Kindred Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Kindred analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Kindred analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
9.2Hold5Odds
Kindred Biosciences current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Kindred analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Kindred stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Kindred Biosciences, talking to its executives and customers, or listening to Kindred conference calls.
Kindred Analyst Advice Details

Kindred Stock Analysis Indicators

Kindred Biosciences stock analysis indicators help investors evaluate how Kindred Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Kindred Biosciences shares will generate the highest return on investment. By understating and applying Kindred Biosciences stock analysis, traders can identify Kindred Biosciences position entry and exit signals to maximize returns.
Quick Ratio11.58
Fifty Two Week Low3.20
Revenue Growth297.20%
Shares Short Prior Month1.28M
Average Daily Volume Last 10 Day640.13k
Average Daily Volume In Three Month1.34M
Shares Percent Shares Out3.23%
Gross Margins68.82%
Short Percent Of Float4.02%
Forward Price Earnings-25.42
Float Shares33.24M
Fifty Two Week High9.28
Enterprise Value To Ebitda-9.64
Fifty Day Average8.26
Two Hundred Day Average5.69
Enterprise Value To Revenue71.66
Please see Stocks Correlation. Note that the Kindred Biosciences information on this page should be used as a complementary analysis to other Kindred Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Piotroski F Score module to get Piotroski F Score based on binary analysis strategy of nine different fundamentals.

Complementary Tools for Kindred Stock analysis

When running Kindred Biosciences price analysis, check to measure Kindred Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kindred Biosciences is operating at the current time. Most of Kindred Biosciences' value examination focuses on studying past and present price action to predict the probability of Kindred Biosciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kindred Biosciences' price. Additionally, you may evaluate how the addition of Kindred Biosciences to your portfolios can decrease your overall portfolio volatility.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Equity Search
Search for activelly traded equities including funds and ETFs from over 30 global markets
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Fund Screener
Find activelly-traded funds from around the world traded on over 30 global exchanges
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
The market value of Kindred Biosciences is measured differently than its book value, which is the value of Kindred that is recorded on the company's balance sheet. Investors also form their own opinion of Kindred Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Kindred Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kindred Biosciences' market value can be influenced by many factors that don't directly affect Kindred Biosciences underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kindred Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Kindred Biosciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kindred Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.